Cystic fibrosis

16 trials 3 recruiting MedDRA PT
16 Registered trials
3 Recruiting
7 Unique sponsors
12 Unique IMPs
12 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 2
R Respiratory (ATC R) 10
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Phase III: 7 Phase II: 6 Phase IV: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 16 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 16 trials

Phase III

7 trials
  • Vertex Pharmaceuticals Inc. Commercial
    TEZACAFTOR, DEUTIVACAFTOR, VANZACAFTOR
    2022-503081-74-00 4 countries 2023 n=25 Orphan
    Recruiting
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2023-503230-49-00 3 countries 2024 n=15 Orphan
    Ended
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2023-509563-24-00 3 countries 2025 n=15 Orphan
    Ended
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; TEZACAFTOR, DEUTIVACAFTOR, VANZACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2024-513754-29-00 4 countries 2023 n=15 Orphan
    Recruiting
  • Vertex Pharmaceuticals Inc. Commercial
    TEZACAFTOR, DEUTIVACAFTOR, VANZACAFTOR
    2024-514173-22-00 16 countries 2023 n=331 Orphan
    Ended
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2024-515606-90-00 1 country 2022 n=3 Orphan
    Ended
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2024-515637-14-00 13 countries 2022 n=295 Orphan
    Ended

Phase II

6 trials
  • Boehringer Ingelheim International GmbH Commercial
    BI 1291583
    2022-502835-21-00 6 countries 2024 n=17
    Ended
  • Sciclone Pharmaceuticals International (SG) Pte. Ltd. Commercial
    THYMALFASIN
    2024-518102-41-00 1 country 2021 n=24
    Ended
  • Splisense Ltd. Commercial
    2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANOYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-5-METHYL-URIDINE SODIUM SALT
    2024-511184-28-00 10 countries 2024 n=16 Orphan
    Halted
  • Vertex Pharmaceuticals Inc. Commercial
    DEUTIVACAFTOR; IVACAFTOR; TEZACAFTOR; TEZACAFTOR, DEUTIVACAFTOR, VANZACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR; VX-828
    2025-523400-72-00 11 countries n=80 Orphan
    Pending
  • Azienda Ospedaliera Universitaria Integrata Verona Academic
    TEICOPLANIN
    2024-517820-21-00 1 country 2024 n=12 Orphan
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona Academic
    TAMOXIFEN
    2024-519657-11-00 1 country n=35 Orphan
    Pending

Phase IV

1 trial
  • IRCCS Istituto Giannina Gaslini Academic
    IVACAFTOR; TEZACAFTOR, ELEXACAFTOR, IVACAFTOR
    2024-518785-28-00 1 country n=50 Orphan
    Pending

Phase I (Other)

1 trial

Phase I (First in Human)

1 trial
  • Vertex Pharmaceuticals Inc. Commercial
    IVACAFTOR; VX-522
    2023-504786-23-00 6 countries 2024 n=10
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Vertex Pharmaceuticals Inc. Commercial 9 Phase II, Phase III, Phase I (First in Human) 2
Azienda Ospedaliera Universitaria Integrata Verona Academic 2 Phase II 1
Boehringer Ingelheim International GmbH Commercial 1 Phase II 0
Sciclone Pharmaceuticals International (SG) Pte. Ltd. Commercial 1 Phase II 0
Splisense Ltd. Commercial 1 Phase II 0
Rigshospitalet Academic 1 Phase I (Other) 0
IRCCS Istituto Giannina Gaslini Academic 1 Phase IV 0
New trials by year
2021
1
2022
2
2023
3
2024
5
2025
1
← All indication landscapes